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Abstract Presentation of processed allergen by antigen-
presenting cells to T-helper (Th) lymphocytes, which is
influenced costimulatory signals, cytokines, chemokines,
and regulatory T cells (Tregs), determines the development
of different types of T-cell immunity. The discovery of
Tregs revolutionized the primary concepts of immune
regulation interpreted within the framework of a binary
Th1/Th2 paradigm. Tregs play a central role in the
maintenance of peripheral homeostasis, the establishment
of controlled immune responses, and the inhibition of
allergen-specific effector cells. Recently, some other T-cell
subsets appeared, including Th17 and Th9 cells, which
control local tissue inflammation through upregulation of
proinflammatory cytokines and chemokines. This review
aims to discuss our understanding of the T-cell subset
reciprocal interaction in atopy.
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Introduction
The activity of T lymphocytes is largely dependent on
specialized introduction of antigenic materials by highly
specialized antigen-presenting cells [1]. Thus, dendritic
cells (DCs) are essential for the differentiation of naïve T
cells into T-helper (Th)1, Th2, Th9, Th17, and Th22
effector T-cell subsets [2] via release of cytokines and
other cofactors (Fig. 1). The differentiation of naïve T cells
into Th2 cells is induced in the presence of interleukin (IL)-
4. Allergen-specific Th2 cells acting through the effects of
released IL-4 and IL-13 induce immunoglobulin class
switching to IgE and clonal expansion of naive and IgE-
positive memory B cells. Cross-linking of IgE bound to
FcεRI (high-affinity receptor for IgE) on the effector mast
cells and basophils results in the release of vasoactive
amines (including histamine); lipid mediators (eg, prosta-
glandin D, platelet-activating factor, leukotriene [LT]C4,
LTD4, and LTE4); chemokines (CXC-chemokine ligand
8 [CXCL8], CXCL10, CC-chemokine ligand 2 [CCL2],
CCL4, and CCL5); and cytokines such as IL-4, IL-5, and
IL-13, leading to the development of type 1 immediate
hypersensitivity reaction [3]. Then, after 6 to 12 h, should a
late-phase allergic reaction occur, it appears due to the
migration of allergen-specific T cells, which are reactivated
and clonally expand under the influence of chemokines and
other cytokines at the site of allergen exposure. The major
effector cells are eosinophils; however, Th1 cells, mast
cells, and basophils also contribute at this phase [3]. The
cellular chronic late-phase response, which is mostly driven
by allergen-specific T cells activated by continuous allergen
exposure, is the driving force for the persistent inflamma-
tion and/or tissue remodeling responsible for the chronic
symptoms of allergic disease [4].
Effector T-cell Subsets
Naive T lymphocytes are primed by DCs that mature and
migrate from peripheral tissues to the T-cell areas of
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cytokines [5]. Two distinct subsets of DCs have been
described in humans. Myeloid DCs (mDCs) [6] express
Toll-like receptor (TLR2) through TLR6 and TLR8 and
produce IL-12 in response to the bacterial and viral stimuli.
Plasmocytoid DCs (pDCs) express TLR7 and TLR9 and
release large quantities of type 1 interferons during the
outcome of antiviral immune responses [5, 7–9]. pDCs
directly suppress the ability of mDCs to generate effector T
cells [10]. pDCs are capable of stimulating the development
of regulatory T cells (Tregs), probably via the inducible
costimulatory molecule (ICOS) ligand–dependent pathway
[8, 10]. It has been shown that the depletion of pDCs in the
lungs results in lack of tolerance to inhaled antigens [10,
11]. The other two DC populations that are present at
inflammatory sites of the skin in atopic dermatitis are the
classical Langerhans cells and the inflammatory dendritic
epidermal cells [12]. It has been recognized that inflamma-
tory dendritic epidermal cells activate the Th1-cell subset.
Classical Langerhans cells induce the Th2-cell subset [13].
Furthermore, the expression of IgE FcεRI on the surface of
DCs and Langerhans cells is not specific to atopic eczema
but rather determined by the type of inflammatory status in
various inflammatory skin diseases. [14].
It has been demonstrated that stem cell factor, the ligand
for c-kit, which is a receptor tyrosine kinase type III, affects
the synthesis of IL-6 and Jagged-2, the ligand of Notch.
Engagement of Notch on the T cells with Jagged on DCs and
T-cell receptors with major histocompatibility complex-II–
coupled peptide induces priming of Th cells [15]. Thus, Notch
affects the Th-cell differentiation by promoting the Th2 and
Th17 development but shows no effect on Th1 response [16].
Apoptosis-resistant DCs effectively generate antigen-specific
Th2 cells in vitro and in vivo and induce IgE responses in
vivo independent of the sensitization status of the host [17].
Th1 and Th2 Cells
The subsets of CD4
+ Th lymphocytes are categorized on
the basis of their distinct cellular functions and cytokine
secretion capacities [18]. Originally, two subsets—Th1 and
Th2 lymphocytes—were described, which accounted for a
binary Th1/Th2 paradigm. Since this time, new Th subsets
have been recognized as important players in immune
regulation. They include well-characterized Tregs as well as
newly described proinflammatory Th17 or Th9 cell
lineages. In the near future, it is likely that new Th subsets
will be described and characterized. The imbalance between
 
   




   
 
     
 









Fig. 1 The differentiation of naïve T cells. Depending on the
adjuvanticity of the substances co-exposed with the antigen and status
of the cells and cytokines in the microenvironment, naïve T cells can
differentiate into T-helper (Th)1, Th2, Th9, Th17, and Th22 types of T
cells. Based on their respective cytokine profiles, responses to
chemokines, and interactions with other cells, these T-cell subsets
can promote different types of inflammatory responses. IFN interfer-
on, IL interleukin, TGF transforming growth factor, TNF tumor
necrosis factor
140 Curr Allergy Asthma Rep (2011) 11:139–145various T-cell subsets accounts for different immune
pathologies, including atopy.
Peripheral T-cell clones differentiate into these subsets
using self-reinforcing transcriptional circuitries that involve
major transcriptional regulators: T-box expressed in T cells
(Tbet) in Th1 cells, trans-acting T-cell–specific transcription
factor (GATA-3) in Th2 cells, forkhead box P3 (FoxP3) in
Tregs, and retinoid-related orphan receptor (ROR)γt/RORα
in Th17 cells. It has been recognized that the counter-
regulation between the T-cell effector subsets is crucial in
immune regulation and in maintaining the balance between
different types of the immune response [19–22]. Thus, the
activation of Tbet inhibits both Th2 cell–mediated eosino-
phil recruitment and Th17 cell–mediated neutrophil recruit-
ment into the airways [23]. An association between a
specific Tbet haplotype and allergic asthma in children has
been suggested [24].
Th2 cells predominantly mediate IgE responses and
allergic inflammation and are also involved in immunity to
parasites [3, 25]. There are likely to be several mechanisms
of Th2 profile dominance in atopic disease. It has been
postulated that Th1 cells are prone to activation and
apoptosis, as their high IFN-γ–producing fraction and
CXCR3
+ T cells in particular show increased apoptosis in
atopic individuals [26]. Th1 cells are involved in cell-
mediated defense against intracellular microorganisms and
in promotion of memory IgG responses. Their phenotype is
dominated by IL-2, IFN-γ, and tumor necrosis factor-β
cytokine profiles. Th1 cells differentiate after stimulation
with IL-12, IL-18, and IL-17. It must be emphasized that
Th1 cells also engage in the effector mechanisms of allergic
disease. It has been recognized that they induce apoptosis
of keratinocytes in atopic dermatitis. In asthma, these cells
induce apoptosis of epithelium and bronchial smooth
muscle cells [27, 28].
The phenotype of Th2 cells is characterized by secretion
of proinflammatory cytokines IL-4, IL-5, and IL-13, which
are clustered on chromosome 5q in close proximity with
granulocyte-macrophage colony-stimulating factor. These
cytokines are associated with pathogenesis of IgE and
eosinophilia. Th2 polarizing factors include monocytic
chemotactic protein 1 and OX40 ligand [29]. OX40 ligation
upregulates IL-4 production, which in turn promotes Th2
polarization [29]. Thymic stromal lymphopoietin (TSLP) is
a novel growth factor produced by epithelial cells that
promotes the proliferation and differentiation of committed
B-cell progenitors. It can substitute for the activity of IL-7,
the B-cell growth and maturation factor. TSLP plays an
essential role in allergic inflammation at the epithelial cell
and DC interface [30] and activates human mDCs to induce
inflammatory Th2 responses [31]. TSLP levels are in-
creased in asthma [32]. TSLP-induced DCs mature and
migrate into the draining lymph nodes and trigger the
adaptive phase of allergic immune response. TSLP induces
OX40L expression in DCs, which induce the differentiation
of allergen-specific naive CD4
+ T cells to inflammatory
Th2 cells [33].
Recently, IL-25 (IL-17E), a member of the IL-17 family
of immunoregulatory cytokines, was shown to regulate
Th2-type immunity. Blocking of IL-25 in an experimental
model of allergic asthma prevented airway hyperrespon-
siveness and suppressed IL-5 and IL-13 synthesis, as well
as eosinophil infiltration, goblet cell hyperplasia, and serum
IgE secretion [34].
Regulatory T Cells
The discovery of Tregs contributed tremendously to the
understanding of the mechanisms of peripheral tolerance
and induction of Th1 or Th2 immunity [35]. Tregs are
characterized by their IL-10 and transforming growth factor
(TGF)-β secretion capacities [36]. Tregs suppress allergen-
induced specific T-cell activation. They also suppress
effector cells of allergic inflammation such as mast cells,
basophils, and eosinophils [37, 38] as well IgE production
[38–40]. Notably, Treg-derived cytokines IL-10 and TGF-β
induce synthesis of noninflammatory IgG4 and IgA
isotypes, respectively [37]. Several subsets of Tregs
showing distinct phenotypes and regulatory effects have




+ Tregs and the induc-
ible type 1, IL-10–secreting Tregs [41]. Furthermore,
regulatory subsets of CD8
+ T cells, γδ T cells, DCs, IL-
10–producing B cells, natural killer cells, and resident
tissue cells, which may promote the generation of CD4
+
Tregs, have been described [42].
The mechanisms by which Tregs induce peripheral
tolerance to allergens may go beyond the effects of
cytokines produced by these cells. They may directly
interact with DCs and compete with naïve T cells in a
physical manner by creating aggregates around DCs and in
this way inhibit their maturation [43]. In addition, Tregs
downregulate the expression of CD80/CD86 on DCs [43].
Naturally occurring Tregs express high cytotoxic T-
lymphocyte antigen-4 (CTLA-4). CTLA-4 is a CD28
family member that binds CD80/CD86. However, it does
so with a higher affinity than CD28. In contrast to
stimulatory effects of CD28, CTLA-4 inhibits T-cell
activation [44–46].
Regarding other IL-10–producing cells (eg, monocytes),
compared with healthy controls, their percentage has been
shown to be significantly increased in atopic patients [47].
They preferentially differentiate into SOCS3-expressing,
alternatively activated macrophages, which induce Th2
immune response [47]. The physiologic relevance of this
phenomenon is unclear. IL-10–treated DCs potently sup-
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Th2 cytokine production. These effects are exerted through
endogenous production of IL-10 [48]. At the molecular level,
IL-10 inhibits CD28 and ICOS costimulations of T cells via
Src homology 2 domain-containing protein tyrosine phos-
phatase (SHP)-1 [49]. IL-10 receptor–associated tyrosine
kinase (Tyk)2 acts as a constitutive reservoir for SHP-1 in
resting T cells. Tyrosine phosphorylates SHP-1 upon IL-10
binding. SHP-1 rapidly binds to CD28 and ICOS costimu-
latory receptors and dephosphorylates them within minutes.
Binding of phosphatidylinositol-3-kinase to either costimu-
latory receptor is inhibited, and downstream signaling is
consequently blocked. In an experimental model, spleen cells
from SHP-1–deficient mice showed increased proliferation
with CD28 and ICOS stimulation in comparison with wild-
type mice, in which cells were not suppressed by IL-10. It
has been postulated that the inhibition of the CD28 or ICOS
costimulatory pathways by SHP-1 may provide a novel
approach for direct T-cell suppression [49]. Src homology 2
domain-containing inositol 5-phosphatase 1 has been
shown consistently to inhibit allergic reactions as a
negative regulator of cytokine and immune receptor
signaling. On the contrary, its deficiency leads to
spontaneous development of allergic-like inflammation in
the murine lung [50].
TGF-β is another key player in immune tolerance. It
exerts its activity in the intestinal mucosa and can induce
immune tolerance to dietary antigens [51]. BALB/c mice
treated orally with ovalbumin (OVA) and TGF-β showed
augmented reduction of OVA-specific IgE and IgG1 anti-
bodies, T-cell reactivity, and immediate-type skin reactions
when compared with mice treated orally with OVA alone
[51]. Thus, local administration of TGF-β may become a
strategy to prevent and treat allergic diseases.
Tregs can directly inhibit the effector cells of allergic
inflammation [52]. Tregs directly inhibit the FcεRI-
dependent mast cell degranulation through cell–cell contact
involving OX40–OX40 ligand interactions [53]. The
depletion or inactivation of Tregs causes enhancement of
the anaphylactic response [2, 53]. IL-10 regulates mast cell
maintenance and proliferation in peripheral tissues [54] and
reduces proinflammatory cytokine release from mast cells
[55]. IL-10 also inhibits eosinophil activities [56].
IL-10 is a potent suppressor of allergen-specific IgE,
whereas it induces IgG4 production [37]. IL-10 decreases ε
transcript expression, thus downregulating IgE production,
while enhancing γ4 transcript expression and increasing
IgG4 production [57]. Supporting evidence has been
provided by studies on Treg–B-cell interaction through
glucocorticoid-induced TNFR-related protein (GITR)/GITR
ligand [58]. The induction of IgG4 and suppression of IgE
in healthy individuals shows the direct influence of Tregs
on B cells [39].
During allergen-specific immunotherapy, the develop-
ment of peripheral T-cell tolerance is characterized mainly
by the generation of allergen-specific Tregs, which suppress
proliferative and cytokine responses against the major
allergens [37, 38, 59–67]. Moreover, local FoxP3
+CD25
+
T cells in the nasal mucosa and their increased numbers after
immunotherapy were demonstrated [68]. Treg-derived IL-10
not only generates tolerance in T cells but also regulates
specific isotype formation and skews the specific response
from an IgE to an IgG4-dominated phenotype [38]. IL-10 is a
potent suppressor of total and allergen-specific IgE, while it
simultaneously increases IgG4 production. During allergen-
specific immunotherapy, increases in allergen-specific IgG4
and IgG1, with 10- to 100-fold increases in their serum levels,
were observed [69, 70].
Th17 Cells
Th17 cells have been shown to induce host protection
against extracellular pathogens and tissue inflammation [20,
71, 72]. Differentiation of Th17 (IL-17A– and IL-17 F–
producing) cells is induced by IL-6, IL-21, IL-23, and TGF-
β [2]. Th17 cells have been implicated in the pathogenesis
of autoimmune diseases [73]. They are characterized by a
strong IL-17–producing capacity. IL-17 family cytokines
include IL-17A through F, which control inflammatory
responses in the tissue by triggering secretion of proin-
flammatory cytokines and chemokines [71, 74]. Tregs can
suppress Th17 cells and autoimmunity. Activation of Th17
cells can start tissue inflammation [75]. IL-17 has been
shown to coordinate granulocyte influx in allergic airway
inflammation models [76, 77]. A member of the IL-17
family, IL-17 F (IL-25), is designated to the Th2-type
group. It promotes Th2-type response; induces eosinophil-
ia; increases serum IgE and IgG1; and upregulates tissue
expression of IL-4, IL-5, and IL-13 [78–80].
Th9 and Th22 Cells
Th9 represents a novel, distinct population of effector T-
helper cells involved in tissue inflammation [2]. It shows no
suppressive functions. This population is characterized by
IL-9 and IL-10 secretion. These cells differentiate from
naïve cells after IL-4 and TGF-β stimulation. It has been
shown that IL-9 together with TGF-β can contribute to
Th17 cell differentiation, and Th17 cells themselves can
produce IL-9 [81]. Th9 cells have been shown to induce
tissue inflammation In autoimmune diseases, however, the
role of this T-cell subset in allergic responses remains to be
elucidated. Another novel T-cell subset has been demon-
strated in T cells that independently express IL-22 with low
expression levels of IL-17 and play a role in atopic
dermatitis. IL-22 can be protective in animal models of
142 Curr Allergy Asthma Rep (2011) 11:139–145colitis, partially attributable to the induction of epithelial
wound healing and mucus production. Although IL-22 was
originally described as a cytokine produced by Th17 cells, it is
now recognized that IL-22 expression by Th cells can be
induced independently of IL-17 expression. Therefore, regu-
lation of the production of IL-22 could be a potent avenue for
influencingthecourseof inflammatoryepithelial diseases[82].
Conclusions
Many factors contribute to development of the Th2 profile
in atopic individuals. Th2-derived IL-4 and IL-13 exert an
important role in class switching in B lymphocytes that
results in IgE production. Recent evidence on T-cell subset
reciprocal regulation and counterbalance between Th1 and
Th2 cells to Th17 and Tregs has greatly influenced our
understanding of immunoregulation and peripheral toler-
ance. Different types of Tregs control several facets of
allergic inflammation. They regulate IgE versus IgG4 and
drive the allergen-specific antibodies toward the noninflam-
matory and nonanaphylactic phenotype. They also directly
or indirectly inhibit effector cells and consequently restrict
allergic inflammation. The understanding of these insights
into the mechanisms of immunoregulation leads to novel
therapeutic approaches.
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